| A. anti-PPS IgG (µg/ml) |
| Patient groups |
PPS14 Day 0 |
PPS14 Day30 |
PPS23F Day 0 |
PPS23F Day30 |
| Group A (CD4>200) |
5.24±1.65 |
14.23±3.16*** |
1.84±0.80 |
4.74±2.24 |
| Group B (CD4<200) |
5.48±1.86 |
15.68±4.12* |
1.00±0.64 |
1.94±0.66 |
| |
| B. anti-PPS IgM(µg/ml) |
| Patient groups |
PPS14 Day 0 |
PPS14 Day30 |
PPS23F Day 0 |
PPS23F Day30 |
| Group A (CD4>200) |
0.37±0.08 |
0.57±0.15 |
0.16±0.03 |
0.20±0.04 |
| Group B (CD4<200) |
0.21±0.05 |
0.28±0.07 |
0.11±0.02 |
0.14±0.02 |
| C.Opsonophagocytic titers (OPT) |
| Patient groups |
Serotype 14 Day 0 |
Serotype 14 Day30 |
Serotype 23F Day 0 |
Serotype 23F Day30 |
| Group A (CD4>200) |
3.0±0.39 |
4380±1159** |
5±1 |
3979±1131** |
| Group B (CD4<200) |
5±1 |
1807±1307 |
6±1 |
7040±2254* |
Data is represented as mean ± standard error of the mean. * indicates significant
rise in the post vaccination (day 30) antibody levels, μg/ml (panels A, B) or
OPT (panel C) compared to pre-vaccination (day 0) within a group. Pre to post
vaccination changes in a single group were compared using paired t-test and
between groups were compared usinganalysis of co-variance (ANCOVA).*p<0.05,
**p<0.01, ***p<0.001. |
